TIDMINC
RNS Number : 7105V
Incanthera PLC
16 April 2021
16 April 2021
Incanthera plc
("Incanthera" or the "Company")
Grant of options
Incanthera plc, the specialist oncology company focused on
innovative technologies in oncology and dermatology, announces the
grant of the following further options on 15 April 2021, under both
its approved and unapproved share option schemes (the
"Schemes").
The Company has granted 1,575,000 options in aggregate to
Directors, PDMRs and consultants.
Details of the grants to directors and PDMRs are as follows:
Option holder (scheme) Number Exercise Price Options Granted
of as Percentage of
Options Current Issued
granted Share Capital
Tim McCarthy (Approved) 275,000 20p 0.37%
Simon Ward (Approved) 275,000 20p 0.37%
Pawel Zolnierczyk (Approved) 275,000 20p 0.37%
Suzanne Brocks (Approved) 275,000 20p 0.37%
Laura Brogden (Unapproved) 275,000 20p 0.37%
Option Schemes and Grant of Options
The Company adopted the Schemes in 2020, to incentivise
management performance for the benefit of all shareholders by way
of options which are subject to time and performance
conditions.
For the purposes of the Schemes, a maximum of 10 per cent. of
the Company's issued share capital in aggregate, from time to time,
may be issued.
Vesting criteria for options granted under the Schemes are
subject to time and performance conditions as follows:
Amount Vesting Time Condition
36 per cent. ("Tranche On the first anniversary
One") of the date of the grant
32 per cent. ("Tranche On the second anniversary
two") of the date of the grant
32 per cent. ("Tranche On the third anniversary
three") of the date of the grant
Performance Condition: Entering into a commercial agreement
relating to its intellectual property.
The Schemes provide for good/bad leaver provisions and other
standard terms normally associated with such schemes.
Following the grant of options above, the Company will have in
total outstanding options over 7,350,000 ordinary shares,
representing 9.9 per cent. of the Company's issued share
capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
For further information, please contact:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman +44 (0) 7831 675747
tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer +44 (0) 7747 625506
simon.ward@incanthera.com
Suzanne Brocks, Head of Communications +44 (0) 7776 234600
suzanne.brocks@incanthera.com
AQSE Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner / James Lewis +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge / John Howes / Bob Pountney +44 (0) 20 3815
8880
Notification and public disclosure of transactions by persons
discharging managerial responsibilities/ person closely associated
with them.
1. Details of the person discharging managerial responsibilities/person
closely associated
Name
1. Tim McCarthy Chairman
2. Simon Ward CEO
3. Pawel Zolnierczyk PDMR
4. Suzanne Brocks PDMR
5. Laura Brogden PDMR
---------
------------------------------- ----------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position/status As above
------------------------------- ----------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Incanthera plc
------------------------------- ----------------------------------------
b) LEI 2138002HEV4UFBOEXQ97
------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the financial Options over ordinary shares
instrument
------------------------------- ----------------------------------------
b) Identification code GB00BGL7YW15
------------------------------- ----------------------------------------
c) Nature of the transactions Grant of Options
------------------------------- ----------------------------------------
d) Volumes and Prices Volume Price
1. 275,000 20p
------
2. 275,000 20p
------
3. 275,000 20p
------
4. 275,000 20p
------
5. 275,000 20p
------
------------------------------- ----------------------------------------
e) Aggregated information Volume Prices
- Aggregated volume 1,375,000 20p
- Price -------
------------------------------- ----------------------------------------
f) Date of the transactions 15 April 2021
------------------------------- ----------------------------------------
f) Place of the transactions AQSE Growth Market, UK
------------------------------- ----------------------------------------
Notes to Editors
Incanthera is a specialist oncology company focused on
transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXIFMATMTABMLB
(END) Dow Jones Newswires
April 16, 2021 02:00 ET (06:00 GMT)
Incanthera (AQSE:INC)
Historical Stock Chart
From Feb 2025 to Mar 2025
Incanthera (AQSE:INC)
Historical Stock Chart
From Mar 2024 to Mar 2025
